1. KD. Tripathi. Drugs for Peptic ulcer and Gastroesophageal Reflux Disease. Essentials of medical pharmacology. Seventh edition. 2013. Page – 651-653.
2. John L. Wallace and Keith A. Sharkey. Pharmacotherapy of Gastric acidity, Peptic ulcer and Gastroesophageal Reflux disease. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1311-1313.
3. Gerald G. Briggs and Roger K. Freeman. R. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 2960-2965.
4. Wyeth is now a wholly owned subsidiary of Pfizer. Study Evaluating Pantoprazole in Children with Gastroesophageal Reflux Disease (GERD). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on May 2010] [Accessed 24th November 2020] https://clinicaltrials.gov/ct2/show/NCT00300755
5. Takeda. Long-term Pantoprazole Trial in Patients with Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on May 2012] [Accessed 24th November 2020] https://clinicaltrials.gov/ct2/show/NCT00261300
6. Andrzej Dabrowski, Borut Štabuc, and Leonid Lazebnik. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR. NCBI; PMC US National Library of Medicine, National Institute of Health. March 2018. [Accessed 24th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894447/
7. Takeda GmbH. Electronic Medicines Compendium (EMC); [Revised on February 2020] [Accessed 24th November 2020] https://www.medicines.org.uk/emc/files/pil.484.pdf
8. Pharma Pack Hungary Ltd. Heads of Medical Agency (HMA); [Revised on December 2016] [Accessed 24th November 2020] http://mri.cts-mrp.eu/download/NL_H_2751_002_FinalPL_1of2.pdf
9. Pfizer. U.S. Food & Drug Administration. [Revised on May 2012] [Accessed 24th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020987s045lbl.pdf